proteomic profiling
proteomic profiling is a genetic therapy with 52 clinical trials. Historical success rate of 89.5%.
Success Metrics
Based on 34 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
11
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
82.9%
34 of 41 finished
17.1%
7 ended early
0
trials recruiting
52
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Validation of the Proteomic Profiling as a Diagnostic Test for Extra-hepatic Cholangiocarcinoma
Proteomic Profiling to Differentiate Pancreatic and Biliary Adenocarcinomas
Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease
Hepatobiliary Tumors Tissue Samples Acquisition
Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15
Clinical Trials (52)
Validation of the Proteomic Profiling as a Diagnostic Test for Extra-hepatic Cholangiocarcinoma
Proteomic Profiling to Differentiate Pancreatic and Biliary Adenocarcinomas
Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease
Hepatobiliary Tumors Tissue Samples Acquisition
Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15
Temozolomide in Treating Patients With Invasive Pituitary Tumors
Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery
ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease
Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab
Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy
Biomarkers in Bone Marrow and Blood Samples From Older Patients With Acute Myeloid Leukemia Treated With Cytarabine-Based Therapy
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers
Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate Biopsy
Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants
Biomarkers in Urine Samples From Patients With Wilms Tumor
Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who Are Undergoing Lung Resection for Suspicious Stage I Lung Lesions
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 52